Quantcast

Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium

December 5, 2008

REDWOOD CITY, Calif., Dec. 5 /PRNewswire-FirstCall/ — Genomic Health,
Inc. (Nasdaq: GHDX) today announced that the company will present results from
four studies at the 31st Annual San Antonio Breast Cancer Symposium, taking
place December 10-14, 2008, at the Henry B. Gonzalez Convention Center. Two
of the studies analyze Oncotype DX(R), the company’s multi-gene expression
test that physicians currently use to predict the likelihood of chemotherapy
benefit as well as the likelihood of recurrence for women with early-stage
breast cancer.

Following are details for each embargoed session (all times are Central
Standard Time):

    -- Thursday, December 11, 2008, 4 p.m. - 4:15 p.m.
       Abstract #25
       Oral presentation (General Session 2): "GRB7-dependent pathways are
       potential therapeutic targets in triple-negative breast cancer"
       Presenter: Joseph Sparano, M.D., Montefiore-Einstein Cancer Center, New
       York
       Location: Exhibit Hall D

    -- Friday, December 12, 2008, 7 a.m. - 9 a.m.
       Abstract #2066
       Poster presentation (Poster Session II: Prognosis and Response
       Predictions: Biomarkers -- Methods): "Quantitative gene expression
       analysis using Oncotype DX in ductal carcinoma in situ that is adjacent
       to invasive ductal carcinoma"
       Presenter: Rick Baehner, M.D., Helen Diller Family Comprehensive Cancer
       Center at the University of California, San Francisco
       Location: Exhibit Hall B

    -- Friday, December 12, 2008, 5 p.m. - 7 p.m.
       Abstract #3049
       Poster presentation (Poster Session III: Tumor Cell and Molecular
       Biology: Hormonal Factors and Receptors): "Associations between
       estrogen receptor (ER) Alpha expression levels and ER genotypes"
       Presenter: Daniel Hayes, M.D., University of Michigan Health System,
       Ann Arbor
       Location: Exhibit Hall B

    -- Saturday, December 13, 2008, 10 a.m. - 10:15 a.m.
       Abstract #53
       Oral presentation (General Session 5): "Risk of distant recurrence
       using Oncotype DX in postmenopausal primary breast cancer patients
       treated with anastrozole or tamoxifen: a TransATAC study"
       Presenter: Mitch Dowsett, Ph.D., Royal Marsden Hospital, London
       Location: Exhibit Hall D

About Oncotype DX(R)

Oncotype DX is the first and only multi-gene expression test commercially
available that has clinical evidence validating its ability to predict the
likelihood of chemotherapy benefit as well as recurrence in early-stage breast
cancer. Additionally, the test report provides quantitative scores for
certain individual genes. Oncotype DX has been extensively evaluated in
eleven clinical studies involving more than 4,000 breast cancer patients,
including a large validation study published in The New England Journal of
Medicine and a chemotherapy benefit study published in the Journal of Clinical
Oncology. To date, 7,500 physicians have ordered more than 75,000 tests, and
both Medicare and private health plans covering approximately 90 percent of
U.S. insured lives provide reimbursement for Oncotype DX through contracts,
agreements or policy decisions. Both the American Society of Clinical
Oncology (ASCO) and the National Comprehensive Cancer Network recommend the
use of Oncotype DX for patients with node-negative breast cancer that is
estrogen-receptor positive and/or progesterone-receptor positive. For more
information about Oncotype DX, please visit http://www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on
the development and commercialization of genomic-based clinical laboratory
services for cancer that allow physicians and patients to make individualized
treatment decisions. In 2004, Genomic Health launched its first test,
Oncotype DX(R), which has been shown to predict the likelihood of breast
cancer recurrence and the likelihood of chemotherapy benefit in a large
portion of early-stage breast cancer patients. The company was founded in
2000 and is located in Redwood City, California. For more information, please
visit http://www.genomichealth.com.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score
are trademarks or registered trademarks of Genomic Health, Inc. All other
trademarks and service marks are the property of their respective owners.

SOURCE Genomic Health, Inc.


Source: newswire



comments powered by Disqus